Fennec Pharmaceuticals Inc (FENC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Fennec Pharmaceuticals Inc (FENC) has a cash flow conversion efficiency ratio of 0.063x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.38 Million) by net assets ($37.67 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Fennec Pharmaceuticals Inc balance sheet quality to measure how much of total assets are equity-financed.
Fennec Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Fennec Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check FENC cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Fennec Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fennec Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pekat Group Bhd
KLSE:0233
|
0.033x |
|
Omega Flex Inc
NASDAQ:OFLX
|
0.007x |
|
Medios AG
XETRA:ILM1
|
0.021x |
|
Standard Biotools Inc
NASDAQ:LAB
|
-0.083x |
|
Zhejiang Meilun Elevator Co Ltd
SHG:603321
|
0.006x |
|
Broedrene A&O Johansen A/S Series B
CO:AOJ-B
|
-0.019x |
|
NEXCOM International Co Ltd
TWO:8234
|
0.017x |
|
JinGuan Electric Co Ltd
SHG:688517
|
0.019x |
Annual Cash Flow Conversion Efficiency for Fennec Pharmaceuticals Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Fennec Pharmaceuticals Inc from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see FENC company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $35.05 Million | $-12.47 Million | -0.356x | +92.26% |
| 2024-12-31 | $-5.87 Million | $26.98 Million | -4.595x | -411.49% |
| 2023-12-31 | $-11.62 Million | $-17.14 Million | 1.475x | -79.02% |
| 2022-12-31 | $-2.57 Million | $-18.06 Million | 7.029x | +879.53% |
| 2021-12-31 | $15.77 Million | $-14.22 Million | -0.902x | -68.09% |
| 2020-12-31 | $29.07 Million | $-15.60 Million | -0.536x | +29.69% |
| 2019-12-31 | $11.88 Million | $-9.06 Million | -0.763x | -107.78% |
| 2018-12-31 | $21.31 Million | $-7.83 Million | -0.367x | -169.84% |
| 2017-12-31 | $26.76 Million | $-3.64 Million | -0.136x | +77.13% |
| 2016-12-31 | $3.57 Million | $-2.12 Million | -0.595x | +82.49% |
| 2015-12-31 | $548.00K | $-1.86 Million | -3.398x | -22.59% |
| 2014-12-31 | $613.00K | $-1.70 Million | -2.772x | -282.48% |
| 2013-12-31 | $-1.46 Million | $-2.21 Million | 1.519x | +151.48% |
| 2012-12-31 | $-4.96 Million | $-2.99 Million | 0.604x | -97.75% |
| 2011-12-31 | $-120.00K | $-3.23 Million | 26.883x | +6765.85% |
| 2010-12-31 | $-4.92 Million | $-1.93 Million | 0.392x | +103.39% |
| 2009-12-31 | $406.00K | $-4.69 Million | -11.547x | -226.17% |
| 2008-12-31 | $3.05 Million | $-10.81 Million | -3.540x | -276.50% |
| 2007-12-31 | $14.15 Million | $-13.30 Million | -0.940x | +47.07% |
| 2006-12-31 | $7.58 Million | $-13.47 Million | -1.777x | -190.61% |
| 2005-12-31 | $20.06 Million | $-12.26 Million | -0.611x | -236.82% |
| 2003-12-31 | $33.00 Million | $-5.99 Million | -0.181x | +48.85% |
| 2002-12-31 | $15.31 Million | $-5.43 Million | -0.355x | +33.18% |
| 2001-12-31 | $6.08 Million | $-3.23 Million | -0.531x | -93.96% |
| 2000-12-31 | $9.82 Million | $-2.69 Million | -0.274x | +98.95% |
| 1999-12-31 | $46.73K | $-1.22 Million | -26.189x | -- |
About Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has co… Read more